Article Text

Download PDFPDF

Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus.
  1. J L Vianna,
  2. H J Haga,
  3. P Tripathi,
  4. R Cervera,
  5. M A Khamashta,
  6. G R Hughes
  1. Lupus Arthritis Research Unit, Rayne Institute, St Thomas's Hospital, London, United Kingdom.


    The antiphospholipid syndrome was initially described in 1986. To reassess the validity of antiphospholipid antibodies in systemic lupus erythematosus (SLE), 95 patients with SLE were studied. Their antiphospholipid antibody profile was analysed and correlated with clinical findings such as thrombosis, abortions, or thrombocytopenia. A low prevalence of these antibodies was found (13 patients; 14%) with a high specificity for thrombosis (92%) and abortions (92%). The importance of anticardiolipin antibodies as a risk factor for thrombosis or abortions, or both, in patients with SLE is reaffirmed by this work.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.